S Hiva Nemati1, Zahra Seiedrazizadeh1, Susan Simorgh1, Mahdi Hesaraki1, Sahar Kiani1, Mohammad Javan1,2, Farzad Pakdel3, Leila Satarian4. 1. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. 2. Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. 3. Ophthalmic Research Center, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. Email: l.satarian@royan-rc.ac.ir.
Nearly 0.5-5 percent of vehicular accidents lead to
optic nerve crush (ONC) injuries; serious damages that
could lead to cell degradation and eventual vision loss,
due to the limitations in retinal ganglion cells (RGCs)
regeneration (1).Currently available medical interventions involving
administration of neuroprotective medications such as
corticosteroids to reduce inflammation, or surgery to
remove pressure, have yielded little therapeutic success
(2). Therefore, a large number of injured individuals-mostly of young ages-suffer from blindness (3).
Nevertheless, it is anticipated that stem cells, which have
the potential to cure neurological disorders, may help in
overcoming this issue (4).The following therapeutic methods are currently
employed for neuropathological conditions: protecting
the damaged cells, preventing further degeneration, and
replacing the degenerated cells with cell transplants. RGC
axons transfer the signals induced by visual stimuli in the
eye to the brain’s targets. Since RGC axons are very long
and possess complex pathways, it does not seem logical
to replace the degenerated cells with cell transplants.
However, protecting the degenerating RGCs might be a
promising approach.Due to the protective and regenerative properties of
stem cells, various types of these cells, including adult,
embryonic and induced pluripotent stem cells at different
levels of differentiation, have been studied in a variety of
retinal disease models (5).NPCs are located in the adult brain or derivatives from
pluripotent stem cells. In the adult brain, they are found
in two defined areas named subventricular zone (SVZ),
which is around the ventricles of cerebral cortex, and
subgranular zone (SGZ), located in the hippocampus.
These parts of the brain are in charge of generating new
neural cells. An injury or disease leading to neuronal loss
and inflammation in the adult CNS will activate the NPCs
by increasing their proliferation and migration rates.
Studies have demonstrated that NPCs act mostly through two main regenerative approaches: cell replacement and
bystander effects (6).In general, according to previous observations,
conditioned medium properties and low integration of
NPCs in retina, have led to the production of only a few
regenerated axons from integrated cells. Application of
NPCs is currently regarded as a more promising strategy
for protecting the degenerating RGCs, due to their ability
to secrete valuable neurotrophic factors (6).Nonetheless, very few studies have examined the
beneficial effects of NPC transplantation in the context
of RGCs and photoreceptor cell defects in different
eye diseases (7). Notably, these studies shared the
fact that NPCs could protect the remaining RGCs and
photoreceptors. However, functional replacement seems
to be rare particularly in the case of RGCs that have long-distance innervating axons compared to the short-distance
targeting axons of photoreceptors.In this study, we aimed to assess the therapeutic
potentials of NPCs in an ONC mouse model. We induced
differentiation of human embryonic stem cells (hESCs)
into NPCs, and subsequently injected them into tail veins
of the ONC mice, in which ONC was induced two days
prior to the injections. The purpose of this experiment was
to determine the effects of NPCs on optic nerve function
and probable long-term protection by evaluating RGC
survival. Potential improvements of the NPC-conditioned
medium led to secretion of some trophic factors including
CNTF, bFGF and IGF1 (6). In this study, we hypothesized
that intravenous (IV) injection of hESC-NPCs compared to
its conditioned medium can improve functional recovery
in ONC mice by paracrine effects, more efficiently.
Materials and Methods
Culture of hESC and Neuronal differentiation
In this experimental study, the hESC (Royan H6 line,
passage 20) colonies were expanded and passaged
according to the report by Mollamohammadi et al. (8). To
generate expandable NPCs, hESCs were maintained and
differentiated under serum and feeder-free conditions. The
hESCs were induced to generate NPCs in two steps (6).
The adherent colony culture of hESCs was treated with
Noggin (R&D, 1967-NG, 100 ng/ml, USA) for six days
(1) and the treatment was followed in the same medium
with an increased concentration (250 ng/ml) of Noggin
along with retinoic acid (Sigma-Aldrich, R2625, USA)
for an additional six days. After appearance of the rosette
structures, to reduce the contamination by other cells, they
were manually picked up under phase-contrast microscopy
and re-plated on poly-l-ornithine (Sigma-Aldrich, P4707,
USA)/laminin (Sigma-Aldrich, L2020, USA) at a 1:15
volume/volume concentration. These structures were
plated in NPC expansion medium containing DMEM F12,
Knock out serum replacement (KSR) 5%, basic fibroblast
growth factor (bFGF, Royan Biotech, Iran, 100 ng/ml)
and epidermal growth factor (EGF, Sigma-Aldrich, USA,
E9644, 20 ng/ml). After one week, the outgrowing colony like cells were dissociated into single cells by 0.008%
trypsin in 2 mM EDTA solution (Invitrogen, USA, 25300)
and transferred to poly-l-ornithine (1:6)/laminin (1:1000)
coated plates containing fresh NPCs expansion medium.
The neural progenitor cells were passaged every 5-7
days at a ratios of 1:2 or 1:3 and remained proliferative
with a highly homogenous morphology. For spontaneous
differentiation, hNPCs received half the volume medium
changes every 4 days in the absence of growth factors for
30 days.
Immunostaining
Immunofluorescence analysis was done according
to standard protocols. In brief, we started with sample
fixation in 4% paraformaldehyde (PFA, Sigma-Aldrich,
USA, P6148) for 20 minutes at room temperature (RT),
then, permeabilization using 0.1% Triton X-100 for 10
minutes. The samples were then incubated in blocking
solution (10% secondary antibodies host serum) for 1
hour at RT, followed by an overnight incubation with
primary antibodies at 4˚C. Next, the cells were washed
in phosphate buffered saline (BSA) and incubated with
secondary antibodies for 45 minutes in an incubator
at 37˚C temperature. Table S1 (See Supplementary
Online Information at www.celljournal.org) lists the
primary and secondary antibodies used in this work. As
negative control we incubated the cells with secondary
antibodies only after the permeabilization step. Nuclei
were stained by incubating the samples in 4, 6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, USA, D9542, 5
μg/ml) or propidium iodide (Abcam, UK, ab14083) in
PBS for 3 minutes at RT. The analysis was done under a
fluorescent microscope (Olympus, Japan, IX71).
RNA isolation and polymerase chain reaction
Determining hNPCs identity was done by relative gene expression analysis versus
undifferentiated hESCs. For this purpose, total mRNA was isolated from NPCs at passage 10,
and from undifferentiated hESCs in triplicates by RNase Plus Universal Mini Kit (Qiagen,
Germany, 73404). RNA purity and concentration were assessed by a UV/Visible
Spectrophotometer (WPA, Biowave II). Then, the first-strand of cDNA was synthesized by 2
μg of total RNA by the Revert Aid First-strand cDNA Synthesis Kit and random hexamer
primer (Fermentase, USA, k1632) in 20 µl reaction mixture, according to the manufacturer’s
instructions. Quantitative real-time RT-PCR was done in 20 μl PCR reaction containing 12.5
ng of synthesized cDNA in 2 μl and 10 μl 2x Power SYBR Green Master Mix (Applied
Biosystems, USA) and 1 μl of 5 pmole forward and reverse primers. Reactions were run in a
Rotor-Gene 6000 (Corbett Life Science, Australia). All qRT-PCR experiments were performed
using three technical and three independent biological replicates. The amount of mRNA was
normalized against GAPDH mRNA and compared using the ΔΔCt method. Primer
sequences are presented in Table S2 (See Supplementary Online Information at
www.celljournal.org).
Induction of optic nerve crush in mice
Male mice (C57BL/J6), at around 8-10 weeks of age,
were kept on a 12 hours day/night cycle with free access to
food and water. All animal trials were done in compliance
with institutional guidelines and the ARVO statement for
the use of animals in ophthalmic and vision research and
Royan Institute ethic committee (IR.ACECR.ROYAN.
REC.1397.251). The mice were anesthetized using
a 1:4 mixture of xylazine/ketamine intraperitoneally
(i.p). ONC was induced using fine forceps (tweezers
#5B forceps, World Precision Instruments) according
to the protocol in our pervious study (9). In summary,
using an operating microscope (Olympus, Japan) left
optic nerve (for behavioral test group left and right)
was grasped approximately 1 mm from the globe for
5 seconds. Antibiotic ointments mixed of Gentamicin
(Daroupakhsh, Iran) and tetracycline (Daroupakhsh, Iran)
were administered for post-operative infection control.
After ONC, the animals were randomly divided into the
vehicle or hESC-NPCs groups.
Cell transplantation
C57BL/J6 mice were divided in defined groups as
follows: i. Intact, ii. Vehicle, and iii. NPCs group. Unlike
the vehicle and the hESC-NPCs groups, no injuries
were made in the intact group (i.e., healthy mice), which
comprised of mice of the same age as the ones in the other
two groups. For determining the protective effects of
intravenous injection of hESC-NPCs on the crushed nerve
of the mice, the animals were held and fed under optimal
conditions within 60 days from induction of the injury.
On days 2, 4, and 6 after causing the injury, 200 µl of
HBSS was injected to the tail vein of each mouse of the
vehicle group (9) while the mice in the hESC-NPCs group
received 50,000 cells in the same manner. We evaluated
different doses of 100,000 and 50,000 cells and observed
a higher survival rate after IV injection of 50,000 NPCs
(data not shown). On day 60 after injury induction, the
animals underwent behavioral tests and then, the murine
retinas were isolated and subjected to various tests in order
to determine the protective effects of the injected cells.
Visual behavioral test
The visual cliff test was used to analyze depth perception
and the fear of crossing the deep side of the platform in
mice; this method shows the relationship between the eye
and the visual cortex. The mice individually underwent
the test in a box while being recorded on video for 120
seconds. The videos were then analyzed by two condition-blinded persons. The test was done for at least 8 mice in
each group 60 days after the crush. The box was designed
according to a previous study (10). To begin the test, the
mice first entered the shallow area, and then the time
spent to cross the border to the deep area was considered
as the latency time. Also, the mean time spent on staying
in shallow area was measured and compared among the
groups.
Examination of retrograde tracing
Retrograde tracing was used to determine RGC axonal
integrity rate after the crush and treatment. In this
experiment we had four mice in each group. For this
purpose, according to the Paxinos atlas, on a stereotaxic
device, a hole was made in each mouse skull over the
superior colliculus (SC), and 2 µl of 2% DiI was injected
into each SC. After 7 days, the animals were euthanized
and their retinas were extracted after perfusion with
saline and 4% PFA. The retina was then placed on a
microscope slide and photographed under an IX51
Olympus fluorescence microscope.
Comparing neuron survival between groups
After 60 days of optic nerve crush, at least 6 mice from
each group were sacrificed and the eyes were fixed in 4%
PFA overnight. Then, the cornea and lens were cut out and
the retinas were separated to perform immunostaining to
detect the transcription factor Brn3a, which is a marker
of RGC nuclei in the eye. Twelve images were taken of
six retinas from each retina quadrants. The photos were
then examined manually and the number of RGCs was
compared among the groups.
Statistical analysis
GraphPad Prism (version 8, USA) was used to test
the differences in behavioral and whole mount tests.
Values plotted in visual test and the whole mount data
are presented as mean ± SD. ***P<0.001; One way
ANOVA and the Tukey’s post hoc tests were used for
more confirmation.
Results
Generation and characterization of hESC- NPCs
Generation of NPCs from hESC and related cell
morphologies are detailed in Figure 1A. We selected
increasing Noggin concentrations during the first 2
weeks of differentiation by adding RA during days 7-12
of the study Around day 12, hESC-NPCs showed typical
morphology of defined clusters as columnar cells with
rosette structures. The rosette structures were detectable
under phase-contrast microscope. Afterward, they were
manually picked up and re-plated (considered passage 0)
on poly-L-ornithin/laminin-coated plates for expansion.
Fortunately, NPCs were passaged every 5-7 days and
they had uniform spindle-like morphology (Fig .1A, cell
morphology at passage 15).
Fig.1
Characterization of hESC-NPCs. A. Timeline and phase-contrast images of the
differentiation protocol used for generating NPCs from hESCs (scale bar: 200 µm).
B. NPCs gene expression as assessed by qPCR. C.
Fluorescent microscopic images of hESC-NPCs at passage 10-15 after immunostaining for
NESTIN, N-Cadherin, PAX6, OTX2 and SOX2 as neural progenitor markers. Nuclei were
counterstained with DAPI (blue) or PI (red). D. Fluorescent microscopic
images of NPCs immunostaining after 30 days of spontaneous differentiation for TUJ1,
MAP2, and NF as mature neural and GFAP as glial markers. Nuclei were counterstained
with PI (red). hESCs; Human embryonic stem cells, NPCs; Neural progenitor cells, qPCR;
Quantitative polymerase chain reaction, and PI; Propidium iodide.
NPCs were characterized for cellular and molecular key markers at passage 10-15 and
were used in the current study. The NPCs expressed neural progenitor markers including
NESTIN, PAX6, OTX2, N-Cadherin, SOX1 and SOX 2 at both gene and protein levels (Fig.1B,
C), which confirmed their differentiation potency toward various neural cell subtypes.
Moreover, upregulation of OTX2 gene against OLIG2 and
HOXB2 confirmed our NPC population rostral identity and their potency
to differentiate toward retinal lineage. Finally, our spontaneous differentiation analysis
confirmed their neuronal (TUJ1, MAP2 and NF) and glial (GFAP) differentiating potencies
(Fig .1D).Characterization of hESC-NPCs. A. Timeline and phase-contrast images of the
differentiation protocol used for generating NPCs from hESCs (scale bar: 200 µm).
B. NPCs gene expression as assessed by qPCR. C.
Fluorescent microscopic images of hESC-NPCs at passage 10-15 after immunostaining for
NESTIN, N-Cadherin, PAX6, OTX2 and SOX2 as neural progenitor markers. Nuclei were
counterstained with DAPI (blue) or PI (red). D. Fluorescent microscopic
images of NPCs immunostaining after 30 days of spontaneous differentiation for TUJ1,
MAP2, and NF as mature neural and GFAP as glial markers. Nuclei were counterstained
with PI (red). hESCs; Human embryonic stem cells, NPCs; Neural progenitor cells, qPCR;
Quantitative polymerase chain reaction, and PI; Propidium iodide.
NPC intravenous injection does not improve animal
visual behavior
Figure 2A shows a schematic timeline of the
present work. We injected 50,000 NPCs/200 µl HBSS
intravenously via tail vein, 2, 4, and 6 days after the crush.Mice were evaluated by visual cliff test for optic nerve
regeneration. In this test, the time that was spent by the mice to cross the border between the shallow (safe area)
and the deep (latency time) ends, was measured during
two-minute periods. Considering the animals’ fear of
heights, latency time for the mice with healthy vision was
longer. Our data showed that on day 60 post-injury, the
average latency time for intact, vehicle and NPCs groups
were 33.0 ± 6.13, 7.8 ± 3.5 and 14.5 ± 4.5 s, respectively
(Fig .2B).
Fig.2
Study timeline and behavioral test. A. Schematic timeline of the intravenous
injection of cells or HBSS (optic nerve crush time was considered day 0).
B. Visual behavioral test was done 60 days after induction of the
crush. Mouse in the visual cliff box (view from the top) with passing of the border
between shallow (S) and deep area (D), Visual behavioral test was done on day 60 with
non-significant difference of decision time between NPCs and Vehicle group, n=9 for
each group. Values plotted are mean ± SD; unpaired t test. HBSS; Hanks’ balanced salt
solution and NPCs; Neural progenitor cells.
Total time in the safe area had the same trend in all
groups, but the mice in the intact group stayed for a longer
period of time in the shallow area compared to the vehicle
and NPCs groups. Visual Cliff data were analyzed by
one way ANOVA and showed no significant increase in
latency time and time spent in the shallow area in animals
that had received NPCs compared to the vehicle group,
after two months.Study timeline and behavioral test. A. Schematic timeline of the intravenous
injection of cells or HBSS (optic nerve crush time was considered day 0).
B. Visual behavioral test was done 60 days after induction of the
crush. Mouse in the visual cliff box (view from the top) with passing of the border
between shallow (S) and deep area (D), Visual behavioral test was done on day 60 with
non-significant difference of decision time between NPCs and Vehicle group, n=9 for
each group. Values plotted are mean ± SD; unpaired t test. HBSS; Hanks’ balanced salt
solution and NPCs; Neural progenitor cells.
NPCs improved neuroprotection in the retina
Compared to the vehicle groups, significantly higher
RGC nuclei concentrations were found in the NPCs group
as shown by immunofluorescent staining. After extracting
the whole retinas, the RGCs were detected by labeling the
transcription factor Brn3a, which is a marker specifically
used to stain RGC nuclei (Fig .3A). Average cell count
of the whole retinas on day 60 per each group was as
follows: Intact group: 688.68; Vehicle group: 158.66; and
NPCs group: 404.74. Data were analyzed by GraphPad
Prism using one-way ANOVA and Tukey’s multiple
comparisons test. Based on data obtained from counting
the nuclei stained with Brn3a, the NPCs group showed a
significant improvement compared to the vehicle group
(P<0.0001, Fig .3B).
Fig.3
Survival rate in hESC-NPCs group compared to the vehicle and intact on day 60 post crush.
A. Whole mount retinas sta ined with Brn3a against RGCs nuclei (scale
bar: 100 µm). B. Average numbers of viable RGCs counted in 30-38 fields
of four retinas from each of the intact, vehicle and NPCs groups. Data are presented
as mean ± SD. hESCs; Human embryonic stem cells, NPCs; Neural progenitor cells, RGCs:
Retinal ganglion cells, and ***; P<0.001, unpaired t test.
Survival rate in hESC-NPCs group compared to the vehicle and intact on day 60 post crush.
A. Whole mount retinas sta ined with Brn3a against RGCs nuclei (scale
bar: 100 µm). B. Average numbers of viable RGCs counted in 30-38 fields
of four retinas from each of the intact, vehicle and NPCs groups. Data are presented
as mean ± SD. hESCs; Human embryonic stem cells, NPCs; Neural progenitor cells, RGCs:
Retinal ganglion cells, and ***; P<0.001, unpaired t test.
Retrograde tracing test was used to inspect the healthy
RGC axons that deliver signals from the brain to the
retina. For this purpose, DiI was injected in the SC of the
mouse brain and was tracked in RGC bodies at 5 to 7 days
post-injection. Photographs taken from at least four eyes
in each group, were compared qualitatively. The results
indicated a significant higher axon survival rate in the
NPCs group compared to the vehicle group (Fig .4).
Fig.4
Retrograde tracing in the hESC-NPCs group compared to the vehicle
and intact groups on day 60 after Crush. Retrograde tracing using DiI showed
more RGC intact axons in the whole mount retinas of the NPCs-treated group
compared to the vehicle group, n=4 for each group (scale bar: 100 µm). hESCs;
Human embryonic stem cells, NPCs; Neural progenitor cells, and RGCs: Retinal
ganglion cells.
Retrograde tracing in the hESC-NPCs group compared to the vehicle
and intact groups on day 60 after Crush. Retrograde tracing using DiI showed
more RGC intact axons in the whole mount retinas of the NPCs-treated group
compared to the vehicle group, n=4 for each group (scale bar: 100 µm). hESCs;
Human embryonic stem cells, NPCs; Neural progenitor cells, and RGCs: Retinal
ganglion cells.
Discussion
Optic nerve damage, caused by vehicular accidents or
diseases, leads to degeneration RGCs, which have a very
limited regeneration rate in mammals. This will ultimately
cause permanent impaired vision or even blindness. Anti-inflammatory medicines such as corticosteroids as well
as surgical interventions have been proven effective in delaying disease progression and removing the pressure
from the nerve, but these solutions have limited outcomes.
Thus, researches have been looking for novel approaches
like using different stem cells.Over the recent years, stem cells have created new
hope for curing neurodegenerative diseases. Due to their
protective and regenerative potentials, various types of
stem cells such as the NPCs are being used; NPCs are
adult stem cells in the central nervous system that can
nowadays be derived from pluripotent stem cells.Studies have shown that transplanted NPCs are able
to migrate to the injury site, and after homing, they can
apply this bystander effect through multiple displays
including secretion of neurotrophic cytokine (e.g. NGF,
VEGF, GDNF, NT-3, BDNF, etc.) that are vital for neural
protection and can stimulate endogenous repair potentials
of the residing progenitors (11, 12).However, in the case of the trauma-induced
neurodegenerative conditions occurring near a
deleterious inflammatory environment, such as spinal
cord or optic nerve crush injuries, or conditions that
are due to a combination of genetic and environmental
factors [e.g. Alzheimer’s (13), Huntington’s (14), and
ischemic brain injury (15)], a simple replacement of the
lost cells does not seem to be enough. Indeed, a potentially
successful approach to treat such conditions should
provide a multidimensional cross-talk between immune
cells, neural progenitors and damaged mature neurons.
Therefore, NPCs via exerting bystander effects, are still
retained as a fascinating choice for cell transplantation
in CNS diseases. In addition, it was demonstrated that
NPCs can exert immunological properties by expressing
various surface molecules, such as TLRs, chemokine
receptors, integrins and specific cell adhesion molecules
(11). However, the underlying cellular and molecular
mechanisms are not completely understood at this time.
Nonetheless, the results of clinical and preclinical studies
on NPC transplantation in different neurodegenerative
diseases (16) indicates that direct integration and
replacement of the transplanted cells have insignificant
(or even zero) impact on observed functional recovery,
thus making the bystander effect hypothesis stronger
regarding the NPC transplantation approach.According to previous studies, after direct intravitreal
injection of neurotrophic factors such as Ciliary
neurotrophic factor, NT3 and VEGF, prevention of cell
degeneration after the injury was observed in damaged
RGCs (17). Based on the literature, trophic factors help
RGCs to survive, but their use is limited due to high
costs and the invasive nature of repeated injections.
Secreted neurotrophic factors such as PDGF and BDNF
are important for RGC protection (18, 19). NPCs
secrete neurotrophic factors that improve the lesion
microenvironment, thereby providing an appropriate
condition for the repair (20).Numerous studies have confirmed the positive effects
of NPCs on regeneration of peripheral and central nervous tissues (13). Also, NPCs have been proven
effective in protecting neurons and the neural tissue in
neurodegenerative diseases such as Parkinson’s, stroke
and spinal cord injury. Although the complete mechanism
of this effect remains unknown, it is assumed to be a
secondary event, which is dependent on neurotrophic
factors such as IGF, NGF, CNTF, BDNF and FGF2 (12).To date, only a few studies have investigated the
potential effects of human pluripotent stem cell-derived
NPCs on optic nerve regeneration. Banin et al., by
subretinal or intravitreal transplantation of hESC-neural precursors in rat eyes, successfully showed the
potential of these cells for retinal differentiation (21).
Underlying mechanisms of cell therapy in the retina are
still unclear. In addition, considering the complexity of
retinal structure, we hypothesized that RGC regeneration
is possible in the presence of NPC trophic factors.
Therefore, continuous secretion of trophic factors by
the NPCs injected systemically was considered for this
study. Here, we showed that IV injected hESC-derived
NPCs were beneficial for RGC survival without a loss of
efficacy. Some studies on neural stem cell transplantation
in neurological diseases, similarly suggested the function
of neurotrophic factors as an underlying mechanism for
neural regeneration (22, 23).Our study showed that hESCs efficiently differentiated into neural progenitors using the
Noggin protein as BMP- antagonist, and retinoic acid (RA) as a morphogen. The hNPCs
expressed SOX1 and 2, NESTIN, PAX6, OTX2, and N-cadherin, and showed neural subtype
differentiation potencies in vitro. Furthermore, NPCs had high expression
levels of PAX6 and OTX2 markers of anterior brain and retinal differentiating linage cells
(24, 25). According to our previous study, lower passages of NPCs derived from pluripotent
stem cells, could express transcription factors that mostly confirmed the forebrain and
rostral identity (26).Since our NPCs had a rostral identity, they seemed to be suitable therapeutic candidates
for degenerated RGCs. Moreover, we could claim that due to our NPC line homogeny along with
less commitments toward a specific neural cell types, they have the capacity for homing
properly, integrating in the injured optic nerve and releasing appropriate neurotrophic
factors in vivo (27). Subsequently, they could change the inflammatory site
toward noninvasive environment (in the site of injury), which will cause sufficient
improvement as observed in the current study.In the present animal study, C57 mice were used to
provide an optic nerve damage model and on days 2, 4
and 6 each mouse received 50,000 ESC-derived NPCs
over a 6-day period. We selected this cell therapy regimen
since trophic factors are gradually secreted by NPCs.
For selecting the hESC-NPCs dosage, our pilot study
showed that triple IV injections of 50,000 cells is safe and
appropriate.To do this, at least 8 animals were tested in each group
and the results, which were indicative of a cognitive
behavior (i.e., the animal’s fear of height), showed that
different crossing times in the NPCs and vehicle groups
carried no significant relationship; thus, we concluded
that no behavioral improvement was achieved.We found that NPCs significantly increased the
survivability of RGCs compared to the vehicle controls.
The significant neuroprotection offered by hESC-NPCs
was confirmed by retrograde tracing test. This was
performed through the injection of DiI into the SC in the
brain. DiI entered RGCs and moved towards the cell body
through the axons (28). Our results confirmed higher
concentrations of DiI-stained RGCs in the NPCs group
compared to the vehicle group.
Conclusion
These findings created new potentials for treating
optic nerve damage using ESCs-derived NPCs. Further
investigations should be carried out to help find a proper
treatment for optic nerve damage. Taken together,
human ES-NPCs promoted neuroprotection of RGC in
ONC mice. The ease of transplantation without any side
effects makes hES-NPCs an acceptable therapy for RGCs
degeneration. Clearly, in translating these findings to
the clinical applications, factors such as cell dosage and
immune-related issues remain to be unraveled.
Authors: Thomas V Johnson; Nicholas W DeKorver; Victoria A Levasseur; Andrew Osborne; Alessia Tassoni; Barbara Lorber; Janosch P Heller; Rafael Villasmil; Natalie D Bull; Keith R Martin; Stanislav I Tomarev Journal: Brain Date: 2013-10-30 Impact factor: 13.501
Authors: Silmara de Lima; Yoshiki Koriyama; Takuji Kurimoto; Julia Teixeira Oliveira; Yuqin Yin; Yiqing Li; Hui-Ya Gilbert; Michela Fagiolini; Ana Maria Blanco Martinez; Larry Benowitz Journal: Proc Natl Acad Sci U S A Date: 2012-05-21 Impact factor: 11.205
Authors: Leyan Xu; Jun Yan; David Chen; Annie M Welsh; Thomas Hazel; Karl Johe; Glen Hatfield; Vassilis E Koliatsos Journal: Transplantation Date: 2006-10-15 Impact factor: 4.939